The past decades witnessed a significant stride in deciphering the pathophysiology of
inflammatory bowel disease, which further advanced drug development adding several new …

Despite recent advances in the understanding of the pathogenesis of inflammatory bowel
diseases (IBD) and advent of multiple targeted therapies, approximately one-third of patients …

Despite major advances in the inflammatory bowel diseases field, biomarkers to enable
personalized and effective management are inadequate. Disease course and treatment …

Despite advances in our understanding of the pathophysiology underlying inflammatory
bowel disease, there remains a significant need for biomarkers that can differentiate …

Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the
gastrointestinal tract, with a complex pathogenesis; they are characterized by a significant …

Precision medicine is part of five focus areas of the Challenges in IBD research document,
which also includes preclinical human IBD mechanisms, environmental triggers, novel …

A fundamental first challenge is that current IBD diagnostic and classification schemes, such
as the Lennard-Jones criteria and Montreal classification, 3 do not capture the significant …

For many chronic, complex human diseases like inflammatory bowel disease (IBD), there
are limited treatment options. Although the 21st century has seen remarkable advances in …

Inflammatory bowel disease (IBD)—consisting of ulcerative colitis and Crohn's disease—is a
complex, heterogeneous, immune-mediated inflammatory condition with a multifactorial …

Precision medicine is part of 5 focus areas of the Challenges in IBD Research 2024
research document, which also includes preclinical human IBD mechanisms, environmental …